 | Jonas Oldgren |
Prominent publications by Jonas Oldgren
BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.
METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of ...
| Also Ranks for: Atrial Fibrillation | year warfarin | 150 dabigatran | rates stroke | systemic embolism |
BACKGROUND: The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. In this subgroup analysis, we assess the efficacy and safety of dabigatran in patients who did and did not receive concomitant antiplatelets.
METHODS AND RESULTS: All comparisons used a Cox ...
| Also Ranks for: Dabigatran Patients | antiplatelet therapy | major bleeding | systemic embolism | randomized evaluation |
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
[ PUBLICATION ]
BACKGROUND: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.
METHODS AND RESULTS: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. ...
| Also Ranks for: Warfarin Dabigatran | atrial fibrillation | younger patients | 2 doses | risk major bleeding |
BACKGROUND: Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of bleeding.
METHODS: In this multicenter trial, we randomly assigned 2725 patients with atrial fibrillation who had undergone PCI to triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (for 1 to 3 months) ...
| Also Ranks for: Atrial Fibrillation | united states | dual therapy | pci risk | hazard ratio |
AIMS: After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of patients undergoing PCI due to acute coronary syndrome (ACS) or elective PCI, and those receiving ticagrelor or clopidogrel treatment.
METHODS AND RESULTS: In the RE-DUAL PCI trial, 2725 patients were randomized to dabigatran 110 mg or 150 mg with P2Y12 inhibitor, or warfarin with P2Y12 inhibitor and ...
| Also Ranks for: Dual Therapy | atrial fibrillation | coronary intervention | patients acs | elective pci |
BACKGROUND: The benefit of oral anticoagulation in atrial fibrillation is based on a balance between reduction in ischaemic stroke and increase in major bleeding. We aimed to develop and validate a new biomarker-based risk score to improve the prognostication of major bleeding in patients with atrial fibrillation.
METHODS: We developed and internally validated a new biomarker-based risk score for major bleeding in 14,537 patients with atrial fibrillation randomised to apixaban versus ...
| Also Ranks for: Atrial Fibrillation | major bleeding patients | bleeding score | based abc | gdf15 ctnt |
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation
[ PUBLICATION ]
BACKGROUND: Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation. This prespecified study investigated these ...
| Also Ranks for: Renal Function | atrial fibrillation | major bleeding patients | systemic embolism | dabigatran warfarin |
BACKGROUND: Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of 2·0-3·0. In the Randomised Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, dabigatran versus warfarin reduced both stroke and haemorrhage. We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population.
METHODS: In the RE-LY trial, 18 113 ...
| Also Ranks for: Ratio Control | ly trial | stroke prevention | warfarin interactions | intracranial bleeding |
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin
[ PUBLICATION ]
BACKGROUND: Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required.
METHODS AND RESULTS: The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin. Bleeding rates were evaluated from 7 days before ...
| Also Ranks for: Dabigatran Warfarin | periprocedural bleeding | thromboembolic events | invasive procedures | urgent surgery |
BACKGROUND: There is a modest risk of myocardial infarction (MI) and myocardial ischemic events in patients with atrial fibrillation.
METHODS AND RESULTS: Data from the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy) were used to report rates of MI, unstable angina, cardiac arrest, and cardiac death and the prespecified net clinical benefit and treatment effects of dabigatran versus warfarin. MI occurred at annual rates of 0.82% and 0.81% with dabigatran 110 or ...
| Also Ranks for: Dabigatran Warfarin | myocardial ischemic events | atrial fibrillation | randomized evaluation | anticoagulation therapy |
Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of stent thrombosis and coronary events. Triple antithrombotic therapy, typically comprising warfarin, aspirin, and clopidogrel, is associated with a high risk of bleeding. A modest-sized trial of oral anticoagulation with warfarin and clopidogrel without aspirin showed ...
| Also Ranks for: Triple Therapy | percutaneous coronary | atrial fibrillation | dual antithrombotic | thrombotic events |
The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507]. ...
| Also Ranks for: Patients Noacs | atrial fibrillation | practical guide | heart rhythm | oral anticoagulants |
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
[ PUBLICATION ]
BACKGROUND: Atrial fibrillation is an important cause of morbidity and mortality worldwide, but scant data are available for long-term outcomes in individuals outside North America or Europe, especially in primary care settings.
METHODS: We did a cohort study using a prospective registry of patients in 47 countries who presented to a hospital emergency department with atrial fibrillation or atrial flutter as a primary or secondary diagnosis. 15 400 individuals were enrolled to determine ...
| Also Ranks for: Atrial Fibrillation | 1 year | stroke patients | 47 countries | north america |
BACKGROUND: Oral anticoagulation in addition to antiplatelet treatment after an acute coronary syndrome might reduce ischaemic events but increase bleeding risk. We performed a meta-analysis to evaluate the efficacy and safety of adding direct thrombin or factor-Xa inhibition by any of the novel oral anticoagulants (apixaban, dabigatran, darexaban, rivaroxaban, and ximelagatran) to single (aspirin) or dual (aspirin and clopidogrel) antiplatelet therapy in this setting.
METHODS AND ...
| Also Ranks for: Oral Anticoagulants | acute coronary syndrome | antiplatelet therapy | aspirin clopidogrel | clinically bleeding |
Jonas Oldgren: Influence Statistics
| Concept | World rank |
|---|---|
| tni cardiac mortality | #1 |
| inhibitor asundexian | #1 |
| fxia inhibitor thrombosis | #1 |
| asundexian 20 | #1 |
| npv indication | #1 |
| pacificaf | #1 |
| tni findings | #1 |
| 12694 patients | #1 |
| rely registry analysis | #1 |
| postoperative higher risk | #1 |
| asundexian 50 | #1 |
| openlabel anticoagulation | #1 |
| asundexian compared | #1 |
| primary endpoint asundexian | #1 |
| sweden dabigatran | #1 |
| 82 75 years | #1 |
| therapy dabigatran | #1 |
| health prognosis recurrence | #1 |
| ischemic stroke postoperative | #1 |
| oral anticoagulation ttr | #1 |
| 2 indication | #1 |
| switching anticoagulant | #1 |
| dabigatran warfarin patients | #1 |
| indication tni 01 | #1 |
| patients maximum tni | #1 |
| stair climbing score | #1 |
| asundexian 20 asundexian | #1 |
| peak concentrations asundexian | #1 |
| questionnaire polyvascular | #1 |
| interaction dabigatran | #1 |
| assigned asundexian | #1 |
| warfarin allcause stroke | #1 |
| swedish clinical register | #1 |
| concentrations asundexian | #1 |
| annalgorithms early diagnosis | #1 |
| dose asundexian | #1 |
| tni 04 ppv | #1 |
| warfarin december | #1 |
| start noac | #1 |
| longterm 20year costs | #1 |
| 268 oac | #1 |
| dabigatran daily dabigatran | #1 |
| increase dabigatran | #1 |
| register enrolment | #1 |
| ecg prognostic assessment | #1 |
| troponin electrocardiographic findings | #1 |
| 24 tni 04 | #1 |
| lowest worst score | #1 |
| 110 150 | #1 |
| noacs warfarin treatment | #1 |
Key People For Atrial Fibrillation
Jonas Oldgren:Expert Impact
Concepts for whichJonas Oldgrenhas direct influence:Atrial fibrillation, Patients atrial fibrillation, Myocardial infarction, Coagulation activity, Dabigatran warfarin, Dabigatran dual therapy, Major bleeding, Triple therapy.
Jonas Oldgren:KOL impact
Concepts related to the work of other authors for whichfor which Jonas Oldgren has influence:Atrial fibrillation, Oral anticoagulants, Heart failure, Catheter ablation, Stroke prevention, Major bleeding, Myocardial infarction.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |